Gilead Sciences holds $56.3B in total assets. Shareholders' equity is $23.5B against $22.2B in total debt. Cash and equivalents total $7.6B. The current ratio is 1.97 and debt-to-equity is 0.943. Based on the Q1 2026 filing.